Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06189703 · ClinicalTrials.gov registry record · NA
tRNS Treatment for ADHD Symptoms
A NA study of ADHD, sponsored by Innosphere.
- Active
- Registry status
- NA
- Development phase
- 146
- Enrollment target
- 5
- Study locations
NCT06189703: Active NA study of ADHD, sponsored by Innosphere.
NCT06189703 is a NA study of ADHD that is active but no longer recruiting, run by Innosphere. The registered enrollment target is 146 participants, below the 188-participant average among 75 other ADHD trials with a reported enrollment target (22% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06189703, a NA study of ADHD, is active but no longer recruiting, sponsored by Innosphere.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 146 participants
- Enrollment target
- 5
- Study locations
Study Summary
A randomized, sham-controlled, double-blind clinical trial to examine the safety and effectiveness of tRNS on unmedicated pediatric patients (7-12 years) with ADHD. Subjects will undergo either tRNS or sham treatment for 10 days during a two-week period in a home-simulated environment. Each treatment session is 20 minutes, during which their attention will be maintained using a software game.
Primary Outcome
Change in ADHD symptom severity, measured by total score of parent-reported ADHD-RS questionnaire from baseline to End of Treatment (Week 2) compared to sham control.
Conditions Studied
Interventions
- DEVICE tRNS
Study Locations (5)
Texas
- Baylor College of Medicine Department of Psychiatry & Behavioral Sciences - Houston
- UTHealth Houston - Houston
Massachusetts
- Boston Children's Hospital - Boston
Minnesota
- Mayo Clinic Hospital, Methodist Campus - Rochester
Other
- Hadassah Medical Center - Jerusalem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 146 participants |
| Start Date | 2024-07-15 |
| Est. Completion | 2026-05-30 |
| Phase | NA |
What the registry record for NCT06189703 still lists
NCT06189703 is an interventional study that assigns participants to a tested intervention. The registered 146 participants enrollment target is mid-sized for trials with a published cap, below the 188-participant average among 75 other ADHD trials with a reported enrollment target (22% lower).
The record links to 1 condition, with ADHD appearing as the primary indexed condition, and to 1 intervention - of which tRNS is the first listed.
NCT06189703 lists 5 locations in 4 states (Texas, Massachusetts, Minnesota).
Frequently Asked Questions
What is clinical trial NCT06189703 about?
NCT06189703 is a clinical study titled "tRNS Treatment for ADHD Symptoms". A randomized, sham-controlled, double-blind clinical trial to examine the safety and effectiveness of tRNS on unmedicated pediatric patients (7-12 years) with ADHD. Subjects will undergo either tRNS or sham treatment for 10 days during a two-week period in a home-simulated environment. Each treatmen...
What is the current status of trial NCT06189703?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 146 participants. The study started on 2024-07-15. Estimated completion is 2026-05-30.
What conditions does trial NCT06189703 study?
This clinical trial studies the following conditions: ADHD.
What interventions are being tested in trial NCT06189703?
The interventions under investigation include: tRNS (DEVICE).
Who is sponsoring clinical trial NCT06189703?
This trial is sponsored by Innosphere, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06189703 being conducted?
This trial has 5 study locations across Massachusetts, Minnesota, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for ADHD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06189703's enrollment target sits among peer trials
146 26th of 75 higher than 50 of 75 other ADHD trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other ADHD trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Comparative Efficacy of Organizational Skills Training (OST) and Mindfulness-Based Intervention (MBI)
RECRUITING · NA
-
Target ADHD Executive Working Memory Replication Study
RECRUITING · NA
-
Comparative Efficacy of Organizational Skills Training (OST) and Mindfulness-Based Intervention (MBI)
RECRUITING · NA
-
Fidgeting and Attentional and Emotional Regulation in ADHD
RECRUITING · NA
-
Moms Managing Attention-Deficit/Hyperactivity Disorder (ADHD) Study
RECRUITING · NA
-
A Pilot Study of a Remote ADHD Monitoring Program
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03490929 · 146 participants · Phase 4
CEUS for Blunt Abdominal Trauma in Children
- NCT04755062 · 146 participants · NA
A Culturally-relevant Micronutrient-dense Plant-rich (mNDPR) Dietary Intervention for Native Americans
- NCT04867954 · 146 participants
Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis
- NCT05051618 · 146 participants · NA
Exercise Training for Managing Major Depressive Disorder in Multiple Sclerosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI